United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
By S. Soignet, S. Frankel, D. Douer, M. Tallman, H. Kantarjian, E. Calleja, R. Stone, M. Kalaycio, D. Scheinberg, P. Steinherz and 5 more. Journal of Clinical Oncology, 2001
854 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Ophthalmology
View Paper: https://www.semanticscholar.org/paper/11094d45319f9385f9c426f7f1aef5a22888edef
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia (2003, background): “The projected 18month disease free survival rate was 56%.(10) In this article, we report a single-institution experience demonstrating the efficacy and safety of As2O3, and we demonstrate a high rate of molecular remissions with As2O3 at the time of CR in patients with recurrent APL.”
- Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (2013, neutral): “A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evide”
- Heavy Metals Toxicity and the Environment (2012, positive): “Recent clinical trials have found that arsenic trioxide has therapeutic value in the treatment of acute promyelocytic leukemia, and there is interest in exploring its effectiveness in the treatment of a variety of other cancers [69,70].”